12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga · 06/18 21:06
Gainers
- Tenon Medical (NASDAQ:TNON) stock increased by 168.9% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $6.9 million.
- Azitra (AMEX:AZTR) stock moved upwards by 20.44% to $0.21. The company's market cap stands at $3.2 million.
- Impact BioMedical (AMEX:IBO) shares moved upwards by 13.18% to $0.57. The company's market cap stands at $62.2 million.
- Nutriband (NASDAQ:NTRB) stock rose 12.77% to $3.27. The company's market cap stands at $37.1 million.
- Pulmatrix (NASDAQ:PULM) shares rose 11.64% to $1.63. The company's market cap stands at $5.4 million.
- Agape ATP (NASDAQ:ATPC) stock rose 9.02% to $4.23. The company's market cap stands at $2.7 million.
Losers
- PAVmed (NASDAQ:PAVM) stock declined by 15.5% to $4.36 during Thursday's after-market session. The market value of their outstanding shares is at $35.7 million.
- Cryo-Cell International (AMEX:CCEL) shares decreased by 13.97% to $3.48. The market value of their outstanding shares is at $28.4 million.
- Cellectar Biosciences (NASDAQ:CLRB) shares decreased by 8.97% to $2.54. The market value of their outstanding shares is at $19.8 million.
- Genprex (NASDAQ:GNPX) shares decreased by 8.81% to $0.54. The company's market cap stands at $5.2 million.
- Aspire Biopharma Holdings (NASDAQ:ASBP) shares fell 7.3% to $6.1. The company's market cap stands at $8.2 million.
- OS Therapies (AMEX:OSTX) stock declined by 7.26% to $1.79. The company's market cap stands at $76.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.